NEW YORK--Sept. 18, 2007--Delcath Systems, Inc. (Nasdaq:DCTH) today announced that its Chief Executive Officer, Richard L. Taney, will present tomorrow at the CL King Best Ideas Conference. The Delcath presentation is scheduled for 10:00 AM Eastern Time on Wednesday, September 19, 2007. The event will be held at the Omni Berkshire Place Hotel in New York from September 18 - 19, 2007.

About Delcath Systems, Inc.
Delcath Systems is the developer of percutaneous perfusion technology for organ- or region-specific delivery of therapeutic and chemotherapeutic agents. The Delcath system is currently being tested with the drug melphalan in a Phase III trial of patients with metastatic ocular and cutaneous melanoma in the liver, and a Phase II trial of patients with primary liver cancers and metastatic tumors in the liver from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. The Company's intellectual property portfolio currently consists of 18 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website, www.delcath.com.

About CL King & Associates
CL King & Associates, Inc. was founded in 1972 by Candace King Weir as an independent research boutique firmly committed to providing value-oriented research and analysis of investment opportunities exclusively for institutional investors. CL King is one of the first woman-owned securities firms in the United States and is a self-clearing registered broker/dealer. The firm makes markets in close to 300 securities, with eight industry analysts. CL King seeks to "Discover the Uncovered" by actively searching for underfollowed, unknown companies; more than 42% of the companies covered by the firm are followed by five or fewer sell-side analysts.